全文获取类型
收费全文 | 12435篇 |
免费 | 876篇 |
国内免费 | 317篇 |
专业分类
耳鼻咽喉 | 193篇 |
儿科学 | 584篇 |
妇产科学 | 272篇 |
基础医学 | 1257篇 |
口腔科学 | 270篇 |
临床医学 | 1052篇 |
内科学 | 1115篇 |
皮肤病学 | 228篇 |
神经病学 | 764篇 |
特种医学 | 904篇 |
外国民族医学 | 4篇 |
外科学 | 1750篇 |
综合类 | 1347篇 |
预防医学 | 286篇 |
眼科学 | 158篇 |
药学 | 574篇 |
11篇 | |
中国医学 | 97篇 |
肿瘤学 | 2762篇 |
出版年
2023年 | 202篇 |
2022年 | 283篇 |
2021年 | 411篇 |
2020年 | 460篇 |
2019年 | 375篇 |
2018年 | 315篇 |
2017年 | 376篇 |
2016年 | 418篇 |
2015年 | 421篇 |
2014年 | 770篇 |
2013年 | 862篇 |
2012年 | 682篇 |
2011年 | 678篇 |
2010年 | 557篇 |
2009年 | 533篇 |
2008年 | 607篇 |
2007年 | 580篇 |
2006年 | 533篇 |
2005年 | 465篇 |
2004年 | 404篇 |
2003年 | 306篇 |
2002年 | 259篇 |
2001年 | 243篇 |
2000年 | 216篇 |
1999年 | 174篇 |
1998年 | 199篇 |
1997年 | 159篇 |
1996年 | 162篇 |
1995年 | 167篇 |
1994年 | 197篇 |
1993年 | 129篇 |
1992年 | 127篇 |
1991年 | 142篇 |
1990年 | 121篇 |
1989年 | 99篇 |
1988年 | 104篇 |
1987年 | 81篇 |
1986年 | 91篇 |
1985年 | 109篇 |
1984年 | 94篇 |
1983年 | 57篇 |
1982年 | 81篇 |
1981年 | 88篇 |
1980年 | 72篇 |
1979年 | 61篇 |
1978年 | 46篇 |
1977年 | 43篇 |
1976年 | 32篇 |
1974年 | 8篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Could Argyrophilic Nucleolar Organizer Regions count mirror DNA Ploidy in Malignant Salivary Gland Tumors? 下载免费PDF全文
Marwa T HussienManar Ali MohamedShima Gafar MansorDoaa F TemerikSherif Farouk ElgayarEnas Alaa El-din Abd El-Aziz 《Asian Pacific journal of cancer prevention》2022,23(6):1983-1992
Objective: Nucleolar organizer regions (NORs) are DNA coils that transcribe to ribosomal RNA. The NOR-associated protein, termed argyrophilic NOR (AgNOR), was visible within the nucleus by staining with silver nitrate examination via the light microscope. AgNOR counting is a proliferation marker and may help in the diagnosis and prognosis of various neoplastic lesions. Aneuploidy (abnormal DNA content) can predict the progression, survival and prognosis of the tumors. The aim of this study was to evaluate the role of AgNORs, DNA ploidy status, and total S-phase fraction (TSPF) as prognostic parameters in malignant salivary gland tumors (MSGTs). Methods: The current study is a retrospective study on a cohort of MSGTs (N=47), to assess AgNORs using Silver Nitrate stain, DNA index (DI), and TSPF using flow cytometry (FCM). Data including tumor size and site, lymphovascular invasion (LVI), lymph node metastasis (LNM) were collected. Results: The AgNORs count was statistically significant with MSGT type. DI was found to have a significant association with tumor site, tumor size and MSGT type. In addition, TSPF was found to be significantly associated with LVI. A moderate positive correlation was noted between AgNORs count and TSPF. LNM, tumor site, high AgNORs and low DI were all associated with short disease-free survival (DFS) and poor overall survival (OS). Conclusion: The present study revealed that high AgNORs count, DNA aneuploidy and TSPF had a poor influence on MSGTs prognosis. 相似文献
3.
Desmoid-type fibromatosis (DF) is a distinctly rare condition, mostly of younger adults, characterized by the development of locally aggressive tumors of mesenchymal origin. Desmoid tumors (DT) arise either sporadically or in association with FAP (familial adenomatous polyposis), although certain risk factors have also been identified, including pregnancy and antecedent surgical trauma. They can emerge from any connective tissue including muscle, fascia and aponeurosis and are therefore classified, according to location, as intra-abdominal, of the abdominal wall and extra-abdominal. Despite the lack of metastasizing potential, the course can be unpredictable. Various mutations of APC and β-catenin genes, among others, play a catalytic role in the pathogenesis of this neoplastic entity. Surgery has lost its traditional role as first line treatment of the disease and several other treatment methods are being considered. Cytotoxic chemotherapy, non-cytotoxic systemic therapy and targeted therapy have been revealed as part of different treatment regimens. Recent progress regarding DT biology and molecular pathways has led to the development of promising novel biological agents. In any case, a multidisciplinary approach is required and is gradually employed, espe-cially in intra-abdominal DTs. In this review, we aim to present current knowledge on DF and summarize current treatment regimens as well as their effectiveness, with emphasis on the intraperitoneal type of DT. 相似文献
4.
5.
《European journal of medical genetics》2022,65(11):104609
BackgroundGastrointestinal stromal tumors have been detected in 25% of the necropsies performed on NF1 patients, but have been reported only in 7% of NF1 patients in the largest series. Such data imply an important gap between the true presence of tumors and those diagnosed. Few genotype-phenotype relationships have been described but to date none referring to abdominal tumors.ObjectivesEvaluate retrospectively the efficacy of a regular and proactive follow-up of NF1 patients to early diagnose abdominal tumors and report their mutations.MethodsCohort study performed between 2010 and 2020, with 43 NF1 adult patients followed at our Dermatology department.ResultsEight abdominal tumors were diagnosed in six patients, meaning that 14% of the followed patients developed an abdominal tumor. Five patients (83%) were asymptomatic. Five (83.3%) had a family history of NF1 with abdominal tumors (patients 1,2 and 3,4,5 were relatives).ConclusionsAlthough currently gastrointestinal routine screening investigations for asymptomatic patients are not recommended in the guidelines, the family aggregation in our series suggests it should be considered a close follow-up of the relatives of a patient with an NF1-related abdominal tumor. Also, for the first time, two mutations [c.2041C > T (p.Arg681Ter) and c.4537C > T (p.Arg1513*)] have been associated with family aggregation of abdominal tumors in NF1 patients. 相似文献
6.
7.
目的 通过对消化系统常见肿瘤的突变基因进行分析,建立抗肿瘤药物新靶点的成药性评估方法。方法 搜集Integrative Onco Genomics数据库中5种消化系统常见肿瘤(食管癌、胃癌、结直肠癌、肝癌以及胰腺癌)的突变基因数据,从中筛选出各肿瘤中突变率较高的基因,通过canSAR数据库对这些基因或其编码的蛋白进行成药性评估,找到可用于抗肿瘤新药开发的潜在靶点。结果 本研究搜集了5种肿瘤共计35个队列,5445个肿瘤样品。选择每个肿瘤突变率排名前10的基因进一步分析,使用canSAR数据库对未公开研究的突变基因或其编码的蛋白质进行成药性分析,共筛选到17个可成药的潜在药物治疗靶点。结论 本研究建立了一种基于突变基因或其编码蛋白的靶点成药性评估方法,该方法的运用能够为寻找新的抗肿瘤药物治疗靶点提供参考,节省新药开发中靶点筛选的成本与时间。 相似文献
8.
9.
目的:探讨消化道肿瘤中同源重组修复相关基因(homologous recombination repair related gene,HRR)突变的发生情况及临床意义。方法:共92例消化道肿瘤患者,79例患者进行了血液标本HRR检测,53例患者进行了组织标本HRR检测,40例患者同时行血液和组织的HRR基因检测,收集患者基因检测结果及临床相关资料。结果:在79例患者血液标本检测中发现10例(12.6%)有临床意义HRR突变,在53例患者组织标本检测中发现9例(17.0%)有临床意义HRR突变。40例同时行血液和组织的HRR基因检测患者中常见的有临床意义HRR突变为CDK12突变4例(10.0%)、ATM突变3例(7.5%)、BRCA1突变2例(5.0%)。13例有临床意义HRR突变患者中常见共存突变为TP53突变10例(76.9%)、APC突变5例(38.5%)、PIK3CA突变4例(30.8%)。40例患者中13例患者血液和/或组织中有临床意义HRR突变,27例患者血液和组织中均无任何临床意义HRR突变且两组相比,有临床意义HRR突变组肿瘤突变负荷(tumor mutational burden,TMB)为6.17(2.24~11.52),而未携带HRR突变组TMB为0.4(0~3.75),差异有统计学意义(P<0.05)。40例患者组织检测中7例HRR有临床意义的突变,33例无HRR突变,血液检测中10例HRR有临床意义的突变,30例无HRR突变,一致性检验的Kappa值为0.333(P=0.031)。结论:携带有临床意义HRR突变的消化道肿瘤患者TMB更高,血液和组织检测HRR突变有较好的一致性。 相似文献
10.
Anna Vaczlavik Lucas Bouys Florian Violon Gaetan Giannone Anne Jouinot Roberta Armignacco Isadora P. Cavalcante Annabel Berthon Eric Letouzé Patricia Vaduva Maxime Barat Fidéline Bonnet Karine Perlemoine Christopher Ribes Mathilde Sibony Marie-Odile North Stéphanie Espiard Philippe Emy Jérôme Bertherat 《Genetics in medicine》2022,24(2):374-383
PurposeThis study aimed to investigate the genetic cause of food-dependent Cushing syndrome (FDCS) observed in patients with primary bilateral macronodular adrenal hyperplasia (PBMAH) and adrenal ectopic expression of the glucose-dependent insulinotropic polypeptide receptor. Germline ARMC5 alterations have been reported in about 25% of PBMAH index cases but are absent in patients with FDCS.MethodsA multiomics analysis of PBMAH tissues from 36 patients treated by adrenalectomy was performed (RNA sequencing, single-nucleotide variant array, methylome, miRNome, exome sequencing).ResultsThe integrative analysis revealed 3 molecular groups with different clinical features, namely G1, comprising 16 patients with ARMC5 inactivating variants; G2, comprising 6 patients with FDCS with glucose-dependent insulinotropic polypeptide receptor ectopic expression; and G3, comprising 14 patients with a less severe phenotype. Exome sequencing revealed germline truncating variants of KDM1A in 5 G2 patients, constantly associated with a somatic loss of the KDM1A wild-type allele on 1p, leading to a loss of KDM1A expression both at messenger RNA and protein levels (P = 1.2 × 10–12 and P < .01, respectively). Subsequently, KDM1A pathogenic variants were identified in 4 of 4 additional index cases with FDCS.ConclusionKDM1A inactivation explains about 90% of FDCS PBMAH. Genetic screening for ARMC5 and KDM1A can now be offered for most PBMAH operated patients and their families, opening the way to earlier diagnosis and improved management. 相似文献